中国医学装备
中國醫學裝備
중국의학장비
China Medical Equipment
2015年
11期
105-107,108
,共4页
干扰素-α%阿德福韦酯%慢性乙型肝炎%肝功能
榦擾素-α%阿德福韋酯%慢性乙型肝炎%肝功能
간우소-α%아덕복위지%만성을형간염%간공능
Interferon-α%Adefovir dipivoxil%Chronic hepatitis B%Liver function
目的：对比观察阿德福韦酯与干扰素-α对慢性乙型肝炎患者谷丙转氨酶(ALT)复常率、乙型肝炎病毒DNA(HBV-DNA)阴转率及乙型肝炎E抗原(HBeAg)阴转率的影响效果。方法：选取64例慢性乙型肝炎患者，随机将其分为观察组和对照组，每组32例。对照组患者采用干扰素-α治疗；观察组患者采用阿德福韦酯治疗，比较两组患者治疗后的肝功能指标，各时段肝功复常率、HBV-DNA阴转率、HBeAg阴转率及不良反应发生率。结果：两组患者治疗后的谷草转氨酶(AST)、ALT及总胆红素(TBIL)肝功能指标均较治疗前明显改善，差异有统计学意义(t=0.7012，t=0.2058，t=0.1702；P＜0.05)。两组患者在肝功复常率、HBV-DNA阴转率及HBeAg阴转率方面相比无统计学差异。观察组患者不良反应发生率为3.1%，对照组患者不良反应发生率为18.8%，观察组明显低于对照组，两组相比差异有统计学意义(x2=4.010，P＜0.05)。结论：阿德福韦酯治疗慢性乙型肝炎具有与干扰素-α相当的临床疗效，同时能降低不良反应发生率，治疗效果较为安全可靠。
目的：對比觀察阿德福韋酯與榦擾素-α對慢性乙型肝炎患者穀丙轉氨酶(ALT)複常率、乙型肝炎病毒DNA(HBV-DNA)陰轉率及乙型肝炎E抗原(HBeAg)陰轉率的影響效果。方法：選取64例慢性乙型肝炎患者，隨機將其分為觀察組和對照組，每組32例。對照組患者採用榦擾素-α治療；觀察組患者採用阿德福韋酯治療，比較兩組患者治療後的肝功能指標，各時段肝功複常率、HBV-DNA陰轉率、HBeAg陰轉率及不良反應髮生率。結果：兩組患者治療後的穀草轉氨酶(AST)、ALT及總膽紅素(TBIL)肝功能指標均較治療前明顯改善，差異有統計學意義(t=0.7012，t=0.2058，t=0.1702；P＜0.05)。兩組患者在肝功複常率、HBV-DNA陰轉率及HBeAg陰轉率方麵相比無統計學差異。觀察組患者不良反應髮生率為3.1%，對照組患者不良反應髮生率為18.8%，觀察組明顯低于對照組，兩組相比差異有統計學意義(x2=4.010，P＜0.05)。結論：阿德福韋酯治療慢性乙型肝炎具有與榦擾素-α相噹的臨床療效，同時能降低不良反應髮生率，治療效果較為安全可靠。
목적：대비관찰아덕복위지여간우소-α대만성을형간염환자곡병전안매(ALT)복상솔、을형간염병독DNA(HBV-DNA)음전솔급을형간염E항원(HBeAg)음전솔적영향효과。방법：선취64례만성을형간염환자，수궤장기분위관찰조화대조조，매조32례。대조조환자채용간우소-α치료；관찰조환자채용아덕복위지치료，비교량조환자치료후적간공능지표，각시단간공복상솔、HBV-DNA음전솔、HBeAg음전솔급불량반응발생솔。결과：량조환자치료후적곡초전안매(AST)、ALT급총담홍소(TBIL)간공능지표균교치료전명현개선，차이유통계학의의(t=0.7012，t=0.2058，t=0.1702；P＜0.05)。량조환자재간공복상솔、HBV-DNA음전솔급HBeAg음전솔방면상비무통계학차이。관찰조환자불량반응발생솔위3.1%，대조조환자불량반응발생솔위18.8%，관찰조명현저우대조조，량조상비차이유통계학의의(x2=4.010，P＜0.05)。결론：아덕복위지치료만성을형간염구유여간우소-α상당적림상료효，동시능강저불량반응발생솔，치료효과교위안전가고。
Objective:To compare the effect of interferon-α and adefovir dipivoxi in affecting the results of chronic hepatitis B patients with ALT normalization rate, HBV DNA negative conversion rate and HBeAg loss rate.Methods: Sixty four patients with chronic hepatitis B were selected from February 2012 to June 2014 in our hospital,randomly equally divided into the observation group and control group, the observation group patients using interferon therapy mainly, the control group patients mainly using adefovir dipivoxi treatment, to compare liver function before and after treatment, liver function recovery rate, HBV DNA negative rate, HBeAg seroconversion rate at different times and incidence of adverse reactions.Results: Incidence of adverse reactions in observation group was significantly lower than that (3.1%) in the control group, the incidence of adverse reactions of 18.8%; Meanwhile, liver function after treatment of two groups improved significantly than before treatment(t=0.7012,t=0.2058, t=0.1702;P<0.05); liver function recovery rate, HBV DNA negative rate, HBeAg seroconversion rates of two groups were not statistically different(x2=4.010,P<0.05).Conclusion: Adefovir dipivoxil treating patients with chronic hepatitis B has considerable clinical efficacy as interferon-α while reducing the incidence of adverse reactions, more secure and reliable.
